2.
PD-1/PD-L1抑制剂在NSCLC新辅助治疗中的临床研究（已有五项研究结果汇总）
Clinical researches of PD-1/PD-L1 inhibitors in neoadjuvant therapy with NSCLC (summary of five research results)
| Regimen | Trials | Patients phase | Phase | Population | Radiographic responses | MPR | pCR | AE |
| MPR: major pathological response; pCR: pathological complete response; AE: adverse event. | ||||||||
| Nivolumab | CheckMate-159 | Ⅰ-Ⅲa | Ⅱ | 21 | 10% (2/21) | 45% (9/20) | 15% (3/20) | Grade3/4: 1 |
| Atezolizumab | LCMC3 | Ib-Ⅲb | Ⅱ | 54 | 7% (3/45) | 22% (10/45) | 7% (3/45) | Grade3/4: 3 |
| Atezolizumab+nab-paclitaxe and carboplatin | NCT02716038 | Ib-Ⅲa | Ⅱ | 18 | 57% (8/14) | 50% (7/14) | 21% (3/14) | Grade3/4: 12 |
| Nivolumab+carboplatin and paclitaxel | NADIM | Ⅲa | Ⅱ | 46 | 70% (21/30) | 80% (24/30) | 60% (18/30) | Grade3/4: 6 |
| Nivolumab±Ipilimumab | NEOSTAR | Ⅰ-Ⅲa | Ⅱ | 36 | 22% (7/32) | 31% (8/26) | 19% (5/26) | Grade3/5: 3 |